IBM wins $75M contract to streamline FDA regulatory review process

IBM ($IBM) has landed a 5-year $75 million FDA contract to help the agency modernize its regulatory review process by ramping up the agency's computation science capabilities. IBM will analyze regulatory submissions the agency receives from pharmaceutical, medical device and biologic manufacturers with the goal of having an "end-to-end process" that allows FDA to not just have access to industry data, but also the tools needed to analyze it throughout a product's lifespan. Item

Suggested Articles

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

Elligo Health Research will test a harmonized real-word data model built by the FDA.

Just about a year after filing its IPO application BGI hits a big wall with a regulatory review.